Mode
Text Size
Log in / Sign up
Phase 3 N=163 Treatment

Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)

Familial Hypercholesterolemia

Enrolled (actual)
163
Serious AEs
3.7%
Results posted
Jan 2022
Primary outcome: Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 36; 69; 7; 25 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Evolocumab (Biological)
Age
Pediatric · 10+ yrs
Sex
All
Sponsor
Amgen
Primary completion
Jun 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
36; 69; 7; 25; 56; 5
SECONDARY
Percent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HeFH Participants
-36.01; -34.96
SECONDARY
Percent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HoFH Participants
-14.29
SECONDARY
Percent Change From Baseline to Week 80 in Non-HDL-C in HeFH Participants
-32.37; -31.95
SECONDARY
Percent Change From Baseline to Week 80 in Non-HDL-C in HoFH Participants
-13.03
SECONDARY
Percent Change From Baseline to Week 80 in Apolipoprotein B in HeFH Participants
-27.10; -24.15
SECONDARY
Percent Change From Baseline to Week 80 in Apolipoprotein B in HoFH Participants
-19.17
SECONDARY
Percent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HeFH Participants
-28.78; -28.32
SECONDARY
Percent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HoFH Participants
3.71
SECONDARY
Percent Change From Baseline to Week 80 in Apolipoprotein B / Apolipoprotein A1 Ratio in HeFH Participants
-31.00; -29.89
SECONDARY
Percent Change From Baseline to Week 80 in Apolipoprotein B/Apolipoprotein A1 Ratio in HoFH Participants
-2.96
SECONDARY
Change From Baseline to Week 80 in LDL-C in HeFH Participants
-67.2; -63.1
SECONDARY
Change From Baseline to Week 80 in LDL-C in HoFH Participants
-36.5
SECONDARY
Change From Baseline to Week 80 in Estradiol Levels
131.3; 48.2; 283.0
SECONDARY
Change From Baseline to Week 80 in Testosterone Levels
5.282; 3.230; 2.916
SECONDARY
Change From Baseline to Week 80 in Follicle Stimulating Hormone (FSH) Levels
1.88; 0.60; 1.18
SECONDARY
Change From Baseline to Week 80 in Luteinizing Hormone (LH) Levels
2.88; 1.04; 1.76
SECONDARY
Change From Baseline to Week 80 in Adenocorticotropic Hormone (ACTH) Levels
0.78; 0.55; -0.75
SECONDARY
Change From Baseline to Week 80 in Dehydroepiandrosterone Sulfate (DHEA-S) Levels
1.051; 0.956; 0.944
SECONDARY
Change From Baseline to Week 80 in Cortisol Levels
29.81; 51.18; 57.26
SECONDARY
Number of Participants With Liver Function Test Abnormalities at Week 80
0; 0; 0; 0; 0; 0
SECONDARY
Number of Participants With Abnormalities in Levels of Creatine Kinase (CK) at Week 80
0; 0; 1; 0; 0; 0
SECONDARY
Change From Baseline to Week 80 in Carotid Intima-media Thickness (cIMT)
-0.019; -0.012; 0.006
SECONDARY
Change From Baseline in Height at Weeks 24, 48, and 80
158.1; 157.9; 149.4; 2.8; 2.0; 1.6
SECONDARY
Change From Baseline in Weight at Weeks 24, 48, and 80
52.8; 57.0; 42.7; 3.3; 2.3; 3.4
SECONDARY
Number of Participants With Change in Tanner Staging From Baseline to Week 80
13; 20; 6; 14; 21; 6

Summary

The main purpose of this study is to describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab when added to standard of care in children 10 to 17 years of age with familial hypercholesterolemia.

Eligibility Criteria

Inclusion Criteria

Heterozygous Familial Hypercholesterolemia (HeFH):

-Completed Study 20120123 (NCT02392559) while still on assigned investigational product and did not experience a treatment-related serious adverse event

Homozygous Familial Hypercholesterolemia (HoFH):

  • Male or female, ≥ 10 to ≤ 17 years of age at time of enrollment
  • Diagnosis of HoFH
  • On a low-fat diet and receiving background lipid-lowering therapy
  • Lipid-lowering therapy unchanged for ≥ 4 weeks prior to LDL-C screening; fibrates must be stable for at least 6 weeks prior to screening.
  • Fasting LDL-C at screening ≥ 130 mg/dL (3.4 mmol/L)
  • Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

Exclusion Criteria

-Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s); except Study 20120123

HoFH:

  • Moderate to severe renal dysfunction
  • Active liver disease or hepatic dysfunction,
  • Creatine kinase > 3 times the upper limit of normal (ULN) at screening
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02624869). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search